Alzheimer’s Data Questioned; Predicting TBI Outcomes; MS Drug Trials in Ukraine

Studies linked to Cassava Sciences, a company studying simufilam as an investigational treatment for Alzheimer’s disease, continue to be retracted or challenged by medical journals. (New York Times)

People with Alzheimer’s disease had more somatic mutations in neurons than people without Alzheimer’s disease, and those mutations were different from ones seen in normal aging. (Nature)

A blood-based neurofilament light chain (NfL) assay to help assess disease activity risk in relapsing-remitting multiple sclerosis (MS) obtained an FDA breakthrough device designation, testing company Quanterix announced.

An amyloid probability score based on a blood-based diagnostic test, APOE proteotype, and age showed high concordance with amyloid PET status. (JAMA Network Open)

A machine-learning algorithm analyzed head CTs and clinical data from traumatic brain injury (TBI) patients and predicted 6 months post-injury survival and recovery outcomes. (Radiology)

An accelerated trajectory of cardiovascular risk factors upped the risk of developing Alzheimer’s disease dementia. (Neurology)

About 11% of diagnostic items on the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) demonstrated bias for Black children and for girls, a cross-sectional study showed. (JAMA Network Open)

Russia’s attack on Ukraine is disrupting clinical trials for investigational MS drugs like fenebrutinib, Roche said. (Reuters)

Biogen withdrew its marketing authorization application for aducanumab (Aduhelm) to the European Medicines Agency, the company said.

Former college football players were more likely to have cognitive impairment and recurrent headaches than same-age men in the general population. (JAMA Network Open)

Can diet really affect cognitive decline? (New York Times)